Delaware Court Invalidates Two Amgen Patents for Repatha
A federal court in Delaware invalidated two of Amgen’s patents for the cholesterol drug Repatha (evolocumab), siding with Sanofi and Regeneron.
Amgen sued the two drugmakers in 2014 for allegedly infringing its patents on antibodies targeting PCSK9, the protein that regulates cholesterol in the body.
The lawsuit in the U.S. District Court of Delaware alleges that Sanofi and Regeneron’s Praluent (alirocumab) infringed on Repatha’s patent targeting the protein. The case went to trial in 2016 and the court found in Amgen’s favor.